Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) are two top pharmaceutical companies that are pursuing growth opportunities. Pfizer is looking to build up and diversify its business as its COVID revenue diminishes. Novo Nordisk's strategy centers around a fast-growing product in Wegovy. The business isn't as diverse as Pfizer's, but the upside Wegovy possesses could make up for that. Which of these stocks should growth investors buy today?

Pfizer has been raking in the profits and free cash flow from its COVID-19 vaccine and pill. Even though that likely won't be a source of growth for the business moving forward, the company can still reap the rewards. As of July 2, Pfizer had cash and investments totaling nearly $45 billion.

With plenty of resources to tap into, the company is in a great position to invest in its future growth. And Pfizer has already been busy with acquisitions in recent years, including the following deals:

Continue reading

Source Fool.com